23andMe to share customer gene data with GlaxoSmithKline for $300M (tomsguide.com)

Article summary

23andMe, a DNA-testing company, will share its customers' genetic data with GlaxoSmithKline (GSK) for $300 million. The data will be used for medical research, and customers had agreed to let their DNA be used for research when they signed up for the tests. However, some experts are concerned about the privacy implications of this deal. The partnership aims to accelerate the development of new drugs and treatments.

Main themes

• Genetic data sharing
• Medical research
• Privacy concerns
• Pharmaceutical industry
• Discrimination risks
• Regulatory frameworks

What commenters say

• Sharing genetic data with pharmaceutical companies can lead to breakthroughs in medical research and treatment development.
• The deal raises concerns about privacy and the potential for genetic data to be used for discriminatory purposes.
• Customers who opted-in to research when signing up for the tests are willing participants in the advancement of medical science.
• The partnership may ultimately benefit individuals with genetic diseases, but it also poses risks to their privacy and potential insurance discrimination.
• Regulatory frameworks, such as HIPAA, may not provide sufficient protection for individuals' genetic data.
• Some argue that trying to keep DNA secret is a losing game and that preventing discrimination is a more effective strategy.